NCT01585558View on ClinicalTrials.gov

Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 16, 2006

Primary Completion Date

August 19, 2008

Study Completion Date

September 18, 2008

Conditions
AtrophyVaginal Diseases
Interventions
DRUG

Ospemifene (Dose 1)

DRUG

Ospemifene (Dose 2)

DRUG

Placebo

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
collaborator

QuatRx Pharmaceuticals

INDUSTRY

lead

Shionogi

INDUSTRY

NCT01585558 - Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus | Biotech Hunter | Biotech Hunter